Sarpogrelate, an antagonist of 5-HT2A receptor, treatment reduces restenosis after coronary stenting

被引：0
|
作者：
Fujita, M
Mizuno, K
Ho, M
Miwa, K
机构：
[1] Kyoto Univ, Coll Med Technol, Kyoto 606, Japan
[2] Nippon Med Coll, Chiba Hokusoh Hosp, Chiba, Japan
[3] Kawasaki Social Insurance Hosp, Kawasaki, Kanagawa, Japan
[4] Kansai Elect Power Hosp, Osaka, Japan
来源：
CIRCULATION | 2002年 / 106卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2927
引用
收藏
页码：592 / 592
页数：1
相关论文
共 50 条
  • [21] Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling
    Rashid, M
    Manivet, P
    Nishio, H
    Pratuangdejkul, J
    Rajab, M
    Ishiguro, M
    Launay, JM
    Nagatomo, T
    LIFE SCIENCES, 2003, 73 (02) : 193 - 207
  • [22] 5-HT2A receptor antagonist M100907 reduces serotonin synthesis: An autoradiographic study
    Hasegawa, Shu
    Fikre-Merid, Maraki
    Diksic, Mirko
    BRAIN RESEARCH BULLETIN, 2012, 87 (01) : 44 - 49
  • [23] Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In Vivo
    Yadav, Prem N.
    Kroeze, Wesley K.
    Farrell, Martilias S.
    Roth, Bryan L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (01): : 99 - 105
  • [24] Effects of 5-HT1A Receptor Antagonist and 5-HT2A Receptor Agonist on Morphine Withdrawal
    Ramezani, Mahdi
    Shahidi, Siamak
    Afshar, Simin
    Habibi, Parisa
    Hashemi-Firouzi, Nasrin
    NEUROCHEMICAL JOURNAL, 2024, 18 (02) : 321 - 330
  • [25] Progress Towards the Synthesis of a Photoisomerizable Antagonist of the 5-HT2A Receptor
    Robert, Noelle
    Streu, Craig
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S111 - S111
  • [26] 5-HT1A receptor sensitivity after 5-HT2A receptor downregulation
    Hensler, JG
    Truett, KA
    BIOLOGICAL PSYCHIATRY, 1996, 39 (07) : 116 - 116
  • [27] Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease
    Miyazaki, Masanori
    Higashi, Yukihito
    Goto, Chikara
    Chayama, Kazuaki
    Yoshizumi, Masao
    Sanada, Hiroaki
    Orihashi, Kazumasa
    Sueda, Taijiro
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (04) : 221 - 227
  • [28] Different effects of the 5-HT2A receptor agonist DOI and the 5-HT2A receptor antagonist altanserin on D2 receptor binding in the rat brain
    Nikolaus, S.
    Wittsack, H.
    Beu, M.
    Antke, C.
    Hautzel, H.
    Mori, Y.
    Mamlins, E.
    Antoch, G.
    Mueller, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S635 - S635
  • [29] Evaluation of structural effects on 5-HT2A receptor antagonism by aporphines: Identification of a new aporphine with 5-HT2A antagonist activity
    Ponnala, Shashikanth
    Gonzales, Junior
    Kapadia, Nirav
    Navarro, Hernan A.
    Harding, Wayne W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (07) : 1664 - 1667
  • [30] The role of 5-HT2A receptor and 5-HT2A/5-HT1A receptor interaction in the suppression of catalepsy
    Naumenko, V. S.
    Bazovkina, D. V.
    Kondaurova, E. M.
    Zubkov, E. A.
    Kulikov, A. V.
    GENES BRAIN AND BEHAVIOR, 2010, 9 (05) : 519 - 524
12345